Table 3. The 50% inhibitory concentration (IC50) of cisplatin (in μM) on the proliferation of human NSCLC-lines in combination with zoledronic acid.

	LCLC-103H	H1650	H1975	A549	H358
Control	0.19±0.01	4.39±0.21	0.35±0.15	1.27±0.62	8.08±1.51
Zoledronic acid (10 μM)	0.13±0.11*	1.62±0.4*	0.37±0.12	1.7±0.7	4.9±0.71*
Zoledronic acid (25 μM)	0.007±0.003*	0.29±0.11*	0.15±0.07*	1.75±0.89	2.59±0.32*
Zoledronic acid (50 μM)	<0.001*	0.26±0.12*	0.024±0.01*	0.89±0.43	1.27±0.26*

In combination, zoledronic acid reduced the concentration of cisplatin for the same inhibitory level (n=5).

^*p<0.05 to untreated control.